Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03976648
Recruitment Status : Recruiting
First Posted : June 6, 2019
Last Update Posted : May 14, 2020
Sponsor:
Information provided by (Responsible Party):
Galapagos NV

Brief Summary:
This study is the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study is to see how GLPG1690 is tolerated in participants with systemic sclerosis and whether there are any side effects in a long-term treatment period.

Condition or disease Intervention/treatment Phase
Sclerosis, Systemic Drug: GLPG1690 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Orally Administered GLPG1690 in Subjects With Systemic Sclerosis
Actual Study Start Date : July 18, 2019
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : July 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scleroderma

Arm Intervention/treatment
Experimental: GLPG1690 Drug: GLPG1690
film-coated tablets of GLPG1690 for oral use




Primary Outcome Measures :
  1. Number of adverse events (AEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [ Time Frame: From start of study medication in study GLPG1690-CL-204 through day 30 after last dose in study GLPG1690-CL-206 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects who completed the 24-week treatment period of Study GLPG1690-CL-204 and who according to the investigator's judgment may benefit from long-term treatment with GLPG1690.

Exclusion Criteria:

  • Any condition or circumstances that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03976648


Contacts
Layout table for location contacts
Contact: Galapagos Medical Information +32 15 342 900 medicalinfo@glpg.com

Locations
Layout table for location information
United States, California
Pacific Arthritis Care Center Recruiting
Los Angeles, California, United States, 90045
UCLA Rheumatology Recruiting
Los Angeles, California, United States, 90095
United States, Florida
RASF Clinical Research Center Recruiting
Boca Raton, Florida, United States, 33486
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
United States, Texas
Metroplex Clinical Research Center Recruiting
Dallas, Texas, United States, 75231
UT Physicians Center for Autoimmunity Recruiting
Houston, Texas, United States, 77030
Belgium
UZ Gent Recruiting
Gent, Belgium, 9000
UZ Leuven Recruiting
Leuven, Belgium, 3000
Italy
Azienda Ospedaliero Universitaria Careggi Recruiting
Firenze, Italy, 50139
Ospedale San Raffaele S.r.l. - PPDS Recruiting
Milano, Italy, 20132
Spain
Hospital Universitario Vall d'Hebron Recruiting
Barcelona, Spain, 8035
Hospital Universitario 12 de Octubre Recruiting
Madrid, Spain, 28041
United Kingdom
University Hospital Aintree Recruiting
Liverpool, United Kingdom, L9 7AL
Royal Free Hospital Recruiting
London, United Kingdom, NW32QG
Sponsors and Collaborators
Galapagos NV
Investigators
Layout table for investigator information
Study Director: Dick de Vries, MD Galapagos NV
Layout table for additonal information
Responsible Party: Galapagos NV
ClinicalTrials.gov Identifier: NCT03976648    
Other Study ID Numbers: GLPG1690-CL-206
2019-001279-34 ( EudraCT Number )
First Posted: June 6, 2019    Key Record Dates
Last Update Posted: May 14, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Sclerosis
Pathologic Processes
Connective Tissue Diseases
Skin Diseases